Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?

IF 15.4 1区医学 Q1 HEMATOLOGY

Lancet Haematology Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI:10.1016/S2352-3026(24)00205-9

Chenggong Li, Heng Mei

引用次数: 0

查看原文本刊更多论文

抗BCMA/GPRC5D双特异性CAR T细胞治疗复发或难治性多发性骨髓瘤：1+1大于2吗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Haematology HEMATOLOGY-

CiteScore

26.00

自引率

0.80%

发文量

323

期刊介绍： Launched in autumn 2014, The Lancet Haematology is part of the Lancet specialty journals, exclusively available online. This monthly journal is committed to publishing original research that not only sheds light on haematological clinical practice but also advocates for change within the field. Aligned with the Lancet journals' tradition of high-impact research, The Lancet Haematology aspires to achieve a similar standing and reputation within its discipline. It upholds the rigorous reporting standards characteristic of all Lancet titles, ensuring a consistent commitment to quality in its contributions to the field of haematology.